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Despite public health efforts toward reducing 
body lead burden, exposure to lead hazards 
remains an international environmental health 
problem (Brown et al. 2005; Graber et al. 2010; 
Haefliger et al. 2009; Hozhabri et al. 2004; 
Kaiser et al. 2001; Mayan et al. 2001; Nichani 
et al. 2006; Olivero-Verbel et al. 2007; Rubin 
et al. 2002; Safi et al. 2006; Zhang et al. 2009). 
Lead hazards, including paint in toys and con-
sumer products, contaminants in foods and 
herbal medicines, and residential contamina-
tion from dust, water lines, and soil continue to 
threaten children’s health (Bryant 2004; Clark 
et al. 2009; Dixon et al. 2009; Edwards et al. 
2009; Gould 2009; Jacobs et al. 2002; Karri 
et al. 2008; Lin et al. 2010; Sathyanarayana 
et al. 2006). In the United States, contaminated 
older housing stock (built before 1950) contin-
ues to expose significant numbers of children 
to elevated lead environments (dust and soil) 
(Gaitens et al. 2009; Jacobs et al. 2002; Kemp 
et al. 2007; Meyer et al. 2005, 2008). Thus, 
improving our understanding of how the brain 
manages lead exposure throughout life and at 
all exposure levels continues to be an important 
area for research.
Cognitive and executive dysfunction, 
learning disabilities, and antisocial behav-
iors are among the impairments attributed 
to lead exposure in children that persist into 
adulthood (Dietrich et al. 1993b; Needleman 
and Gatsonis 1990; Needleman et al. 1996; 
Wright et al. 2008). Lead exposure, even at 
levels < 10 μg/dL, has been associated with 
these adverse effects in children (Bellinger 
et al. 1992; Canfield et al. 2003a, 2004; 
Chandramouli et al. 2009; Lanphear et al. 
2005). Although much is known regard-
ing the neurotoxicity of lead, how lead pro-
duces these clinical deficits remains poorly 
understood. The influence of lead exposure 
on the developing central nervous system 
and the mechanisms by which lead disrupts 
brain metabolism in children are complex 
(reviewed by Bressler and Goldstein 1991; 
Finkelstein et al. 1998; Lidsky and Schneider 
2003; Toscano and Guilarte 2005; White 
et al. 2007). Toscano and Guilarte (2005) 
devised a conceptual framework illustrating 
the effects of developmental lead exposure at 
glutamatergic synapses and associated signal 
pathways. Summarizing data from various 
experimental models of developmental lead 
exposure, the evidence supports a reduced 
number of synaptic N-methyl-d-aspartate 
(NMDA) excitatory amino acid receptors 
(reviewed by Toscano and Guilarte 2005). 
Lead may act as a calcium analog in neurons, 
with exposure inhibiting glutamate release 
through binding to the NMDA receptor in 
an age-dependent and region-specific man-
ner, which could produce functional differ-
ences despite uniform concentrations within 
the brain. Thus, different regions of the brain 
can demonstrate variable amounts of injury 
despite having equivalent lead exposure.
Clinical neuroimaging studies in children 
with low to moderate (up to 40 μg/dL) blood 
lead levels tend to have few specific anatomi-
cal findings described as characteristic of lead 
exposure. Neural changes, such as microscopic 
structural and chemical disruptions, at levels 
below the detection limits of conventional 
imaging modalities such as computed tomog-
raphy or magnetic resonance imaging (MRI) 
must exist if lead is indeed the source of cog-
nitive deficits and adverse behavioral out-
comes. Therefore, a different in vivo imaging 
approach is needed to determine neurochemi-
cal alterations. Proton magnetic resonance 
spectroscopy (MRS) acquired within an MRI 
examination provides an in vivo measure of 
brain metabolites such as N-acetyl aspartate 
(NAA), creatine and phosphocreatine (Cr), 
glycerolphosphocholine and phosphocholines 
(Cho), myo-inositol (mI), and a composite 
of glutamate and glutamine (GLX) at con-
centration levels on the order of 1–10 mil-
limolar (mM) (Cecil and Jones 2001). These 
brain metabolites reflect the functional status 
of neural structures, such as neurons, axons, 
glia, as well as myelin and cellular membrane 
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Ba c k g r o u n d: Childhood lead exposure adversely affects neurodevelopment. However, few studies 
have examined changes in human brain metabolism that may underlie known adverse cognitive and 
behavioral outcomes.
oB j e c t i v e: We examined the association between mean childhood blood lead levels and in vivo 
brain metabolite concentrations as adults, determined by proton magnetic resonance spectroscopy 
(MRS) in a birth cohort with documented low-to-moderate lead exposure.
Me t h o d s : Adult participants from the Cincinnati Lead Study [n = 159; mean age (± SD), 20.8 ± 
0.9 years] completed a quantitative, short-echo proton MRS protocol evaluating seven regions to 
determine brain concentrations of N-acetyl aspartate (NAA), creatine and phosphocreatine (Cr), 
cholines (Cho), myo-inositol, and a composite of glutamate and glutamine (GLX). Correlation and 
multiple linear regression analyses were conducted.
re s u l t s: Mean childhood blood lead levels were associated with regionally specific brain metabolite 
concentrations adjusted for age at imaging and Full-Scale intelligence quotient. Adjusted analyses 
estimated for a unit (micrograms per deciliter) increase in mean childhood blood lead concentra-
tions, a decrease of NAA and Cr concentration levels in the basal ganglia, a decrease of NAA and a 
decrease of Cho concentration levels in the cerebellar hemisphere, a decrease of GLX concentration 
levels in vermis, a decrease of Cho and a decrease of GLX concentration levels in parietal white mat-
ter, and a decrease of Cho concentration levels in frontal white matter.
co n c l u s i o n s: Gray-matter NAA reductions associated with increasing childhood blood lead levels 
suggest that sustained childhood lead exposure produces an irreversible pattern of neuronal dysfunc-
tion, whereas associated white-matter choline declines indicate a permanent alteration to myelin 
architecture.
key w o r d s : basal ganglia, brain, cerebellum, frontal lobe, gray matter, lead exposure, magnetic 
resonance spectroscopy, white matter. Environ Health Perspect 119:403–408 (2011).  doi:10.1289/
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components; however, measurement of neu-
rotransmitters such as dopamine, serotonin, 
and others is below the detection threshold.
Two groups have examined childhood 
lead exposure by employing either one of the 
two standard MRS acquisition approaches. 
First, Trope et al. (1998) were the first to 
apply magnetic resonance spectroscopic imag-
ing (MRSI) by evaluating a 10-year-old boy 
with a history of elevated blood lead levels as 
a toddler (51 μg/dL at 38 months) and his 
9-year-old cousin, whose blood lead levels 
were characterized as negligible. The MRSI 
technique acquires spectroscopy data simulta-
neously from multiple, juxtaposed regions. A 
reduction in NAA to Cr ratio levels for both 
prefrontal gray and white matter was found 
compared with levels in the subject’s cousin. 
Trope et al. (2001) further replicated this case 
report with 16 subjects having a history of 
elevated blood lead levels before 5 years of age 
(23–65 μg/dL). These subjects were compared 
with age-matched controls composed of sib-
lings or cousins, with an average age of 8 years 
at time of MRSI. Control subjects had blood 
lead levels that never exceeded 10 μg/dL. The 
lead-exposed subjects exhibited a significant 
reduction in NAA to Cr ratio levels in frontal 
gray matter compared with controls. Meng 
et al. (2005) compared spectroscopy data 
obtained using the single volume element 
(voxel) MRS acquisition approach from chil-
dren (n = 6) with blood lead concentrations 
≥ 27 μg/dL and sex-matched control sub-
jects (n = 6) with blood lead concentrations 
< 10 μg/dL, all approximately 11 years of age. 
Lead-exposed children had an average (± SD) 
blood concentration of 37.7 ± 5.7 μg/dL, 
whereas controls averaged 5.4 ± 1.5 μg/dL. 
Bilateral NAA, Cho, and Cr levels in the 
frontal lobes and hippocampi were reported 
as reduced in lead-exposed children relative 
to controls. These studies indicated disrup-
tions in brain metabolism, particularly in the 
frontal lobe (Trope et al. 1998, 2001) and 
hippocampus (Meng et al. 2005). Because of 
the technical and time requirements for con-
centration calibration measurements in pedi-
atric participants, many studies report results 
in the form of metabolite ratios instead of 
concentrations. These ratios are derived from 
integral measurements of areas underneath the 
individual metabolite peaks, with the Cr value 
serving as the denominator of the ratio and 
also serving as an internal reference. This may 
erroneously assume stability in the level of Cr. 
Despite their limitations, the Trope et al. and 
Meng et al. studies remain important, because 
they provided support that early childhood 
lead exposure alters brain metabolism.
The rationale for this current work is to 
determine whether childhood lead expo-
sure permanently alters brain biochemistry 
with lasting effects into adulthood and to 
determine whether there are regional differ-
ences in brain metabolism, particularly in 
gray matter as implicated in the Toscano and 
Guilarte model. We hypothesized that adults 
with significant, documented childhood lead 
exposure would demonstrate evidence of 
altered brain metabolism using proton MRS 
via reduction of NAA. Reductions of NAA 
levels are thought to reflect neuronal and 
axonal disruption, dysfunction and/or loss 
consistent with brain injury.
We employed a single voxel proton MRS 
approach for quantification and selected a 
variety of gray- and white-matter structures 
to match established clinical deficits associ-
ated with lead exposure with corresponding 
regions of the brain involved with regulation 
of a given function. Selection of the frontal 
lobe locations, both medial gray and prefron-
tal white matter, was based upon the cogni-
tive and behavioral features associated with 
lead exposure, particularly executive function-
ing deficits in attention, risk-taking behaviors, 
and inhibition (Bellinger et al. 1994; Canfield 
et al. 2003b, 2004; Coscia et al. 2003; 
Dietrich et al. 2001; Needleman et al. 2002; 
Nigg et al. 2010; Ris et al. 2004; Wasserman 
et al. 1998; Wright et al. 2008). The temporal 
lobe and basal ganglia voxel selection captured 
information for regions involved in limbic 
system and dopaminergic system functioning. 
Mood and memory functions are also impli-
cated in these systems. Sampling within the 
cerebellar hemispheres and vermis was consid-
ered relevant because of the fine motor defi-
cits and noted problems with postural sway 
and balance associated with lead exposure 
(Bhattacharya et al. 1990, 1993, 2006). The 
white matter of the parietal lobe was sampled, 
because this region is thought to be relevant 
for processing speed and aspects of attention. 
Historically, patients with lead encephalopa-
thy have demonstrated lesions in the basal 
ganglia, cerebellum, cortical gray matter, and 
white matter (al Khayat et al. 1997; Atre et al. 
2006; Mani et al. 1998; Tuzun et al. 2002).
Materials and Methods
We have complied with all applicable require-
ments of the United States of America. The 
institutional review boards of the Cincinnati 
Children’s Hospital Medical Center and the 
University of Cincinnati approved the study 
protocol. A certificate of confidentiality for the 
study was obtained from the National Institutes 
of Health. All participants provided written 
informed consent before study participation.
Participants. The study participants were 
recruited from the Cincinnati Lead Study 
(CLS), a longitudinal birth cohort study 
designed to evaluate the effects of low to 
moderate environmental lead exposure. The 
CLS enrolled pregnant women in their first 
or early second trimester of pregnancy who 
visited four prenatal clinics within impover-
ished Cincinnati neighborhoods with a high 
concentration of older, lead-contaminated 
housing. Women were excluded if they were 
known to be addicted to drugs, were dia-
betic, or had any known neurologic or psy-
chiatric malady. Newborns with birth dates 
between 1980 and 1985 were subsequently 
recruited for follow-up studies. Infants were 
excluded if their birth weight was < 1,500 g 
or if genetic or other serious medical issues 
were present at birth. This cohort has been 
described periodically as cognitive, and behav-
ioral and social assessments were completed 
(Dietrich et al. 1985a, 1985b, 1987a, 1987b, 
1990, 1991, 1993a, 1993b, 2001). Newborns 
(n = 305) were followed up quarterly through 
age 5 years, semiannually from 5 to 6.5 years 
of age, again at 10 years, and also between the 
ages of 15 and 17 years. CLS subjects between 
19 and 24 years of age (n = 194) were consec-
utively recruited for this MRS study via mail-
ings, phone calls, and flyers to meet our initial 
sample size goal of 150 CLS participants. This 
size was chosen before initiating the imaging 
aspect of the study, because members of the 
CLS cohort who were pregnant, incarcerated, 
or claustrophobic or had metal implanted 
from surgeries, embedded metal from occu-
pational exposure (e.g., welder), or gunshot 
wounds would not be able have a research 
MRI examination. Subjects who were known 
to be diabetic or who had any known neuro-
logic or psychiatric illness were also excluded. 
The substance use of participants was deter-
mined using a clinical urine toxicology screen-
ing immunoassay for drugs of abuse, which 
evaluated amphetamines, barbiturates, ben-
zodiazepine, cocaine, cannabinoids, opiates, 
and phencyclidine (PCP). (The only positive 
findings for participants were exclusively can-
nabinoids.) The alcohol use within the cohort 
was also assessed via a self-report measure 
previously described (Dietrich et al. 2001). 
Thirty-three subjects were excluded from the 
MRI examination because of the following: 
too large to fit into the MRI scanner (n = 8), 
failure to appear for the appointment (n = 7), 
pregnancy (n = 6), refusal due to claustropho-
bia (n = 6), nonremovable metal in their body 
(n = 5), and inability to give informed consent 
because of cognitive disability (n = 1). Two 
participants diagnosed with fetal alcohol syn-
drome as children participated in the imaging 
and spectroscopy session, but their data are 
not included in the analyses. Consistent with 
previous research in this cohort (e.g., Wright 
et al. 2008), we found no demographic or lead 
exposure biases associated with exclusion of 
these members from the analysis.
Enrollment of the participants’ mothers in 
the CLS permitted monitoring of blood lead 
levels for the participants prenatally, at birth, 
every 3 months to 60 months of age, and every Magnetic resonance spectroscopy of the Cincinnati Lead Study
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6 months from 60 to 78 months of age. The 
mean of 23 childhood blood lead assessments 
for each participant from 3 to 78 months of 
age was employed for comparison analyses. 
This mean childhood blood lead value has 
been historically used for comparisons with 
cognitive and behavioral outcomes (Dietrich 
et al. 1991, 1993b). During the first 5 years 
of life, at least one of the quarterly blood lead 
assessments exceeded 10 μg/dL for 99% of the 
CLS cohort. The peak lead exposure occurred 
between 2 and 3 years of age for the partici-
pants. By adolescence, the mean blood lead 
levels for the cohort were 2.8 ± 1.3 μg/dL. 
Data acquisition and processing. All MRI 
and MRS investigations were acquired on a 
1.5 Tesla MR scanner (Signa LX; General 
Electric Medical Systems, Waukesha, WI, 
USA) with a quadrature head radiofrequency 
coil positioned around the head of the par-
ticipant. An axial three-dimensional, inversion 
recovery prepped, fast spoiled gradient-echo 
high-resolution imaging sequence was acquired 
[echo time (TE) 5 msec, repetition time (TR) 
12 msec, inversion time 300 msec; field of 
view = 24 cm × 19.2 cm, 1.5-mm thick with 
contiguous slices, 256 × 192 × 124 matrix for 
a resolution of 0.94 mm × 1 mm × 1.5 mm]. 
Single voxel MRS was acquired with the pro-
ton brain examination (PROBE) software 
(General Electric Medical Systems) using a 
point-resolved spectroscopy acquisition mode 
(PRESS) sequence (TE = 35 msec, TR = 2 sec 
with 64 averages) and with automatic shim-
ming to achieve water line widths of < 5 Hz. 
A reference spectrum, acquired within the 
PROBE acquisition, collected 16 acquisi-
tions of unsuppressed water signal for eddy 
current and baseline corrections. Data were 
processed using the LCModel program, a 
commercially available, user-independent, fre-
quency domain spectral-fitting program that 
provides measures of metabolite concentra-
tions (Provencher 1993). Concentration levels 
of NAA, Cr, Cho, mI, and GLX were deter-
mined. The concentrations are reported in 
institutional units (IU), rather than milli  molar 
levels; individual corrections for magnetic field 
and coil variations, as well as longitudinal 
(T1) and transverse (T2) relaxation effects, 
are not accounted for because of the excessive 
examination times required to determine such 
effects. However, metabolite concentrations 
were adjusted for the amount of cerebro  spinal 
fluid (CSF) in each voxel. Specifically, the 
LCModel software determines the metabo-
lite concentrations assuming a parenchymal 
volume as defined in the MRS acquisition, 
typically 2 cm per voxel side for a total cubic 
volume of 8 cm3. We employed a K-means 
segmentation algorithm using custom software 
for analysis of the high resolution imaging 
sequence so as to determine gray matter, white 
matter, and CSF contributions to each voxel. 
We then applied a correction factor based on 
the ratio of volume of CSF to total paren-
chymal volume and adjusted each metabolite 
concentration accordingly. LCModel also pro-
vides a measure of data quality and reliabil-
ity, reporting the Cramer–Rao lower-bound 
bounds (Provencher 1993). We required the 
metabolite Cramer-Rao value to be < 15% for 
inclusion in data analyses. For a given partici-
pant, regional spectroscopy data not meeting 
the Cramer–Rao lower-bound criteria were 
excluded from analyses. Approximately 98% 
of the > 1,100 sampled voxels of the cohort 
met criteria and were included in the analyses.
Seven single voxels, approximately 8 cc in 
volume, were positioned within the medial 
frontal gray matter, the left frontal white mat-
ter, left parietal white matter, the right tempo-
ral lobe at the superior temporal gyrus, the left 
basal ganglia, left cerebellar hemisphere (gray 
and white matter), and the cerebellar vermis, 
respectively (Figure 1). Although we antici-
pated no laterality differences, the left side 
of the brain was sampled for several reasons: 
a) neural networks associated with language 
function are left lateralized; b) most of the 
study population is right handed and thus 
likely to be left hemisphere dominant; c) the 
right hemisphere is prone to technical fac-
tors (orientation of slice-selective pulses) that 
produce signal artifacts (i.e., scalp lipid signal 
contamination) within the spectrum.
Statistical analysis. We investigated the 
relationship between metabolite levels obtained 
from MRS analyses in seven brain regions with 
mean childhood blood lead level initially using 
Pearson and Spearman cor  relation coefficients. 
Correlation values with an alpha (p < 0.05) 
were considered significant. The metabolites 
examined included NAA, Cr, Cho, mI, and 
GLX. Recognizing that other variables could 
influence the association between metabolite 
levels and blood lead, the impact of covari-
ates on this relationship were also examined 
by analyzing the bivariate relationship of the 
potential covariate with mean childhood blood 
lead level in each of the sampled brain regions, 
using a linear regression. Such variables that 
could potentially contribute included age 
of participant at time of imaging, Full-Scale 
intelligence quotient (FSIQ), current drug 
use (positive only for cannabinoids), sex, birth 
weight, and gestational age at birth. Covariates 
Figure 1. MR images with blue boxes illustrate the locations of spectroscopy voxels acquired in this study of CLS participants. The seven brain regions included 
(A) cerebellar vermis, (B) frontal gray matter and frontal white matter (right side of the figure), (C) parietal white matter, (D) cerebellar hemisphere, (E) temporal 
lobe at the superior temporal gyrus, and (F) basal ganglia. The voxels are acquired in three dimensions with a volume of 8 cc. The figure uses radiological con-
vention for the images, where the left side of the brain appears on the right side of the image.
Vermis  Frontal   Parietal 
Temporal  Cerebellar
hemisphere
Basal ganglia Cecil et al.
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that were independently related to the out-
come in one or more region at p < 0.10 level 
were included in the subsequent multiple lin-
ear regression analyses. For the linear regres-
sion analyses, beta values corresponded to the 
change in metabolite concentration associated 
with a 10-μg/dL increase in the mean child-
hood blood lead level and the 95% confidence 
intervals (CIs) determined for significance.
Results
The CLS participants (n = 159) who com-
pleted the study were predominantly African 
American (93%), between 19 and 23 years 
of age, and demonstrated mean childhood 
blood lead values of 13.3 ± 6.1 μg/dL that 
ranged from 4.7 to 37.2 μg/dL (Table 1). 
Approximately half of the participants were 
male (52%). The FSIQ scores ranged from 
50 to 116 with a mean of 86.8 ± 11.9. 
Approximately half of the participants smoked 
marijuana near the time of the study (48%).
Age at time of imaging and FSIQ were the 
only covariates meeting the criteria established 
a priori for inclusion in the model. Model esti-
mates adjusted for age and FSIQ indicated 
significant inverse associations between mean 
childhood blood level and regional concentra-
tions of several metabolites. Adjusted analyses 
estimated for a unit (micrograms per deciliter) 
increase in mean childhood blood lead concen-
trations, a decrease of NAA (β = –0.05; 95% 
CI, –0.1 to –0.01) and Cr (β = –0.05; 95% 
CI, –0.09 to –0.01) concentration levels in the 
basal ganglia, a decrease of NAA (β = –0.05, 
95% CI, –0.11 to –0.01), and a decrease of 
Cho (β = –0.01; 95% CI, –0.03 to 0.00) con-
centration levels in the cerebellar hemisphere, 
a decrease of GLX (β = –0.07; 95% CI, –0.12 
to –0.02) concentration   levels in vermis, a 
decrease of Cho (β = –0.01; 95% CI, –0.01 
to –0.001), and a decrease of GLX (β = –0.05; 
95% CI, –0.09 to –0.01) concentration levels 
in parietal white matter, and a decrease of Cho 
(β = –0.01; 95% CI, –0.02 to –0.001) concen-
tration levels in frontal white matter (Table 2).
We performed a secondary analysis with 
adjustment for age at the time of imaging 
only, as FSIQ may be included in the causal 
pathway linking lead with abnormal metabo-
lite levels. Results of this analysis were gen-
erally comparable with those shown, except 
that the association between lead and NAA 
concentration in the cerebral hemisphere was 
no longer statistically significant (β = –0.05; 
95% CI, –0.09 to 0.01, p = 0.08).
Discussion
Our study demonstrated an inverse associa-
tion between mean childhood blood lead lev-
els and metabolic concentrations in five of 
the seven sampled regions. These five regions 
included three gray-matter regions (left basal 
ganglia, left cerebellar hemisphere, and the 
cerebellar vermis) and two white-matter 
regions (left frontal and left parietal).
Gray-matter sampling within the brain 
provided information content reflecting 
neuronal health. Two predominantly gray-
matter regions—basal ganglia and cerebellar 
hemisphere—demonstrated a reduction in 
NAA with increased mean childhood blood 
lead   levels. This suggests that childhood expo-
sure to lead is associated with some level of 
neuronal dysfunction occurring within these 
regions. The diminished Cr levels associated 
with increased mean childhood blood lead 
levels further supported impaired neuronal 
functioning, because Cr levels are thought to 
reflect the status of cellular energetics. MRS 
studies reporting results as ratio values with 
Cr levels serving as an internal reference stan-
dard are likely to miss this finding.
We anticipated that NAA would inversely 
correlate with childhood lead exposure in the 
neuroanatomical regions regulating cognitive 
and behavioral domains found to be impaired 
with lead exposure, which include the fron-
tal cortex. From a voxel-based morphomet-
ric (VBM) analysis of the volumetric imaging 
data, we found striking volume loss associated 
with mean childhood lead exposure within the 
Table 1. Relevant participant characteristics from 
the CLS included in the MR spectroscopy study.
Characteristic Values
Age [years (mean ± SD)] 20.8 ± 0.91
Range (years) 19.7–22.9
Race [n (%)]
Black 147 (93)
White 11 (6.9)
Biracial 1 (0.1)
Sex [n (%)]
Female 76 (48)
Male 83 (52)
Mean childhood blood lead level  
[µg/dL (mean ± SD)]
13.3 ± 6.1
Range (µg/dL) 4.65–37.2
Gestational age at birth  
[weeks (mean ± SD)]
39.4 ± 1.7
Range (weeks) 35–43
Birth weight [g (mean ± SD)] 3,106 ± 467
Range (g) 1,814–4,260
IQ-FSIQ (at 7 years) 86.8 ± 11.9
Range  50–116
Marijuana use [n (%)]
Positive  76 (48)
Negative 83 (52)
Table 2. Regression coefficients between mean childhood blood lead and measured regional metabolite 
concentration levels in an unadjusted model and in a model adjusted for age at time of imaging and FSIQ, 
respectively.
Unadjusted Age and FSIQ adjusted
Voxel location Metabolite Beta 95% CI Beta 95% CI
Basal ganglia  
(left)
NAA –0.05 –0.09 to –0.003 –0.05 –0.1 to –0.01*
Cr –0.05 –0.08 to –0.01 –0.05 –0.09 to –0.01*
Cho –0.01 –0.02 to 0.001 –0.01 –0.02 to 0.002
GLX –0.07 –0.16 to 0.02 –0.08 –0.18 to 0.01
mI 0.001 –0.03 to 0.03 0.001 –0.03 to 0.04
Cerebellar hemisphere 
(left)
NAA –0.06 –0.11 to –0.01 –0.05 –0.11 to –0.01*
Cr –0.02 –0.06 to 0.02 –0.02 –0.06 to 0.02
Cho –0.01 –0.03 to 0.00 –0.01 –0.03 to 0.00*
GLX –0.19 0.02 to 0.01 –0.07 –0.15 to 0.01
mI –0.02 –0.07 to 0.02 –0.02 –0.06 to 0.03
Cerebellar vermis 
(midline)
NAA –0.02 –0.05 to 0.01 –0.01 –0.04 to 0.01
Cr –0.02 –0.05 to 0.01 –0.01 –0.04 to 0.01
Cho –0.005 –0.01 to 0.002 –0.005 –0.01 to 0.003
GLX –0.06 –0.11 to –0.01 –0.07 –0.12 to –0.02*
mI –0.001 –0.03 to 0.03 0.01 –0.02 to 0.04
Frontal gray matter 
(medial)
NAA –0.02 –0.04 to 0.01 –0.02 –0.04 to 0.01
Cr –0.01 –0.03 to 0.01 –0.01 –0.03 to 0.01
Cho –0.004 0.01 to 0.002 –0.003 –0.01 to 0.004
GLX –0.03 –0.08 to 0.02 –0.02 –0.08 to 0.03
mI 0.02 –0.01 to 0.04 0.02 –0.01 to 0.04
Frontal white matter 
(left)
NAA –0.02 –0.05 to 0.01 –0.02 –0.05 to 0.02
Cr –0.004 –0.03 to 0.02 –0.004 –0.03 to 0.02
Cho –0.01 –0.02 to –0.004 –0.01 –0.02 to –0.001*
GLX –0.08 –0.15 to –0.004 –0.06 –0.14 to 0.01
mI 0.003 –0.02 to 0.03 0.004 –0.03 to 0.03
Parietal white matter 
(left)
NAA –0.02 –0.05 to 0.004 0 –0.04 to 0.01
Cr –0.01 –0.03 to 0.003 –0.01 –0.02 to 0.01
Cho –0.01 –0.01 to –0.002 –0.01 –0.01 to –0.001*
GLX –0.05 –0.09 to –0.01 –0.05 –0.09 to –0.01*
mI 0 –0.03 to 0.02 –0.001 –0.02 to 0.02
Temporal lobe 
(STG-left)
NAA –0.02 –0.07 to 0.02 –0.02 –0.06 to 0.03
Cr –0.01 –0.04 to 0.01 –0.01 –0.04 to 0.02
Cho –0.01 –0.01 to 0.002 –0.01 –0.01 to 0.002
GLX –0.03 –0.09 to 0.03 –0.03 –0.09 to 0.04
mI –0.02 –0.05 to 0.01 –0.01 –0.04 to 0.02
*p < 0.05. Magnetic resonance spectroscopy of the Cincinnati Lead Study
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medial frontal gray matter (Cecil et al. 2008). 
The absence of a correlation within the medial 
frontal gray matter was unexpected. We specu-
late, however, that if the neurons within the 
frontal cortex affected by lead suffered apopto-
sis, any residual cortex within this region of the 
brain may have viable residual neurons yielding 
appropriate NAA levels. This would then sug-
gest that other sampled brain regions did not 
suffer significant volume loss, but dysfunction 
and possibly reorganization in a diminished 
fashion with NAA or Cho changes.
Increasing childhood mean blood lead 
concentrations were also correlated with GLX 
reductions within the cerebellar vermis as well 
as the parietal white matter. Although proton 
MRS sampled under these conditions does 
not provide information about glutamate 
specifically, the composite measure sampled 
with proton MRS implicates abnormal neuro-
transmitter functioning.
We found an inverse association between 
the mean childhood blood lead levels and the 
Cho concentration levels within the white 
matter of the frontal and parietal lobes and 
the cerebellar hemisphere, respectively. Lead 
can change white-matter organization and 
functioning via altered expression of genes 
essential to myelin formation (Deng and 
Poretz 2001; Zawia and Harry 1995), delayed 
differentiation of oligodendrocyte progenitors 
(Deng and Poretz 2001; Zawia and Harry 
1995), delayed myelin accumulation (Toews 
et al. 1980, 1983), disordered oligodendro-
cyte architecture (Dabrowska-Bouta et al. 
1999), structural changes within the myelin 
sheath and disintegration of the multilamel-
lar structure (Dabrowska-Bouta et al. 2008), 
and astrogliosis (Selvin-Testa et al. 1994; 
Struzynska et al. 2001, 2007).
The VBM analyses (Brubaker et al. 2010; 
Cecil et al. 2008) for this same cohort did not 
show any lead-associated changes in white-
matter volumes. Reductions of Cho concen-
tration levels within white-matter regions of 
the frontal and parietal lobes and the cerebral 
hemisphere were observed without any NAA-
correlated changes. The Cho signal observed 
on proton MRS arises primarily from the 
mobile, intracellular pools of phosphocho-
lines and glycerophosphocholines involved 
in membrane synthesis and degradation 
(Cecil and Jones 2001; Stork and Renshaw 
2005). Phosphatidylcholine head groups 
from myelin are not MRS visible, because 
their relaxation times are too short for signal 
detection. Typically, Cho increases on proton 
MRS characterize neoplastic or demyelinat-
ing pathologies. A finding of decreased Cho 
concentration level is unusual, although it has 
been reported in hypomyelination disorders 
(van der Voorn et al. 2006). It may repre-
sent abnormal chemical composition within 
the architecture of myelin. A recent diffusion 
tensor imaging analysis of 91 representative 
members of the CLS cohort revealed lead-
associated reductions in fractional anisotropy 
(FA) within the white matter (Brubaker et al. 
2009). Further interrogation found that the 
changes in FA could be attributed to signifi-
cant changes in radial diffusivity (RD). RD 
primarily reflects alterations in the myelin 
sheath thickness and organizational charac-
teristics. The lead-associated declines in RD 
and the reduction in Cho are consistent with 
abnormal myelin architecture affecting white 
matter organization.
The beta values associated with a 1-μg/dL 
increase in mean childhood blood lead lev-
els for metabolite concentrations are small, 
which is physiologically expected. An MRS 
profile for a brain tumor is typically quite dis-
tinct from a region from an acute stroke. In 
these conditions, metabolite levels dramatically 
change several orders of magnitude because of 
the macroscopically observed changes to the 
brain. For conditions such as low-level lead 
exposure, where the brain appears relatively 
normal without lesions, the model of psychi-
atric diseases such as schizophrenia and bipolar 
disorder can be considered. These conditions 
can be clinically diagnosed with high degrees of 
certainty. However, if a person with a diagnosis 
of a given psychiatric condition has imaging or 
spectroscopy performed in a blinded fashion, it 
is likely to be interpreted within normal limits 
because of the lack of diagnostic features attrib-
uted to the conditions and broad normative 
values in a clinical setting. In contrast, research 
studies of such psychiatric conditions com-
pared with appropriately screened and matched 
healthy control participants can find abnormal 
metabolite levels associated with a psychiatric 
condition. Given that the historical blood lead 
levels of an age- and demographically matched 
control population would not be known from 
childhood, nor would the blood lead levels 
for a young adult be zero, ideal comparison 
studies with the CLS population are not pos-
sible outside of the regression approach applied 
within this study.
Limitations. The lack of correlative find-
ings within the temporal lobe may arise from 
technical factors associated with the proton 
MRS acquisition. Peak broadening due to 
magnetic susceptibility and field inhomogene-
ity arises at the interface between the temporal 
lobe and adjacent structures, including the ear 
and the temporal bone, resulting in incom-
plete water suppression, broad line widths 
of the metabolites, and failure of metabolite 
quantification. A dedicated MRS examination 
optimizing the homogeneity of the tempo-
ral lobe is necessary to clarify the impact of 
lead exposure within the temporal lobe. A 
dedicated study of the hippocampus is also 
warranted from other reports in the literature 
providing experimental evidence.
Conclusions
The neurochemical changes demonstrated in 
the adult participants of the CLS reflect the 
complexities of lead neurotoxicity. Gray-matter 
reduction of NAA with the basal ganglia and 
cerebellum is consistent with the concept that 
sustained childhood lead exposure produces 
an irreversible pattern of neuronal dysfunc-
tion. White-matter choline changes within the 
frontal and parietal lobes suggest a permanent 
alteration to myelin architecture.
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